Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: Current knowledge and clinical significance

Molecules

Volumn 19, Issue 9, 2014, Pages 14304-14315

  Majchrzak, Agata ^a   Witkowska, Magdalena ^a   Smolewski, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Akt kinase; Diffuse large B cell lymphoma; Inhibitor; MTOR kinase; PI3K kinase; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; MOLECULAR LIBRARY; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TARGET OF RAPAMYCIN KINASE;

ADMINISTRATION AND DOSAGE; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MOLECULAR LIBRARY; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; TOR SERINE-THREONINE KINASES;

EID: 84907096988     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190914304     Document Type: Review

References (40)

1. Cultrera, J.L.; Dalia, S.M. Diffuse large B-cell lymphoma: Current strategies and future directions. Cancer Control 2012, 19, 204-213.
2. Campo, E.; Swerdlow, S.H.; Harris, N.L.; Pileri, S.; Stein, H.; Jaffe, E.S. The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications. Blood 2011, 117, 5019-5032.
3. Lenz, G. Novel therapeutic targets in diffuse large B-cell lymphoma. EJC Suppl. 2013, 11, 262-263.
4. Petrich, A.; Leshchenko, V.; Kuo, P.-Y.; Xia, B.; Thirukonda, V.K.; Ulahannan, N.; Gordon, S.; Fazzari, M.J.; Ye, B.H.; Sparano, J.; et al. Akt Inhibitors MK-2206 and Nelfinavir overcome mTOR inhibitor resistance in DLBCL. Clin. Cancer Res. 2012, 18, 2534-2544.
5. Ocana, A.; Vera-Badillo, F.; Al-Mubarak, M.; Templeton, A.J.; Corrales-Sanchez, V.; Diez-Gonzalez, L.; Cuenca-Lopez, M.D.; Seruga, B.; Pandiella, A.; Amir, E. Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumours: Systematic Review and Meta-Analysis. PLoS One 2014, 9, e95219.
6. Akinleye, A.; Avvaru, P.; Furqan, M.; Song, Y.; Liu, D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J. Hematol. Oncol. 2013, 6, 88.
7. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7, 606-619.
8. Zhao, L.; Vogt, P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27, 5486-5496.
9. Okkenhaug, K.; Vanhaesebroeck, B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 2003, 3, 317-330.
10. Shymanets, A.; Prajwal, P.; Bucher, K.; Beer-Hammer, S.; Harteneck, C.; Nurnberg, B. p87 and p101 subunits are distinct regulators determining class IB PI3K specificity. J. Biol. Chem. 2013, 288, 31059-31068.
11. Jason, R. Westin Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma. Clin. Cllymphoma Myeloma Leuk. 2014, doi:10.1016/j.clml.2014.01.007.
12. Manning, B.D.; Cantley, L.C. AKT/PKB Signaling: Navigating Downstream. Cell 2007, 129, 1261-1274.
13. Tasian, S.K.; Teachey, D.T.; Rheingold, S.R. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. Front. Oncol. 2014, 4, 108.
14. Vajpayee, N.; Thakral, C.; Gopaluni, S.; Newman, N.; Gajra, A. Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: A clinicopathological study. Leuk. Res. 2012, 36, 1403-1409.
15. Zaytseva, Y.Y.; Valentino, J.D.; Gulhati, P.; Mark Evers, B. mTOR inhibitors in cancer therapy. Cancer Lett. 2012, 319, 1-7.
16. Pfeifer, M.; Lenz, G. PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma. Cell Cycle 2013, 12, 3347-3348.
17. Pfeifer, M.; Grau, M.; Lenze, D.; Wenzel, S.-S.; Wolf, A.; Wollert-Wulf, B.; Dietze, K.; Nogai, H.; Storek, B.; Madle, H.; et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. USA 2013, 110, 12420-12425.
18. Sehn, L.H. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology 2012, 2012, 402-409.
19. Davis, R.E.; Brown, K.D.; Siebenlist, U.; Staudt, L.M. Constitutive nuclear factor kappaB activity
20. Mahadevan, D.; Chiorean, E.G.; Harris, W.B.; von Hoff, D.D.; Stejskal-Barnett, A.; Qi, W.; Anthony, S.P.; Younger, A.E.; Rensvold, D.M.; Cordova, F.; et al. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer 2012, 48, 3319-3327.
21. Davids, M.S.; Rodon, J.; Abrisqueta, P.; Egile, C.; Ruiz-Soto, R.; Awan, F. Update On The Safety and Efficacy of the Pan Class I PI3K Inhibitor SAR245408 (XL147) in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients. Blood 2013, 122, 4170-4170.
22. Ando, Y.; Inada-Inoue, M.; Mitsuma, A.; Yoshino, T.; Ohtsu, A.; Suenaga, N.; Sato, M.; Kakizume, T.; Robson, M.; Quadt, C.; et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumours. Cancer Sci. 2014, 105, 347-335.
23. Dreyling, M.; Morschhauser, F.; Bron, D.; Bouabdallah, K.; Vitolo, U.; Linton, K.; van Den Neste E.; Mappa, S.; Giurescu, M.; Childs, B.H.; et al. Preliminary Results of a Phase II Study of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, in Patients with Relapsed/Refractory, Indolent or Aggressive Lymphoma. Blood 2013, 122, abstract 87.
24. Kahl, B.; Byrd, J.C.; Flinn, I.W.; Wagner-Johnston, N.; Spurgeon, S.; Benson, D.M., Jr.; Furman, R.R.; Brown, J.R.; Coutre, S.; Lannutti, B.; et al. Clinical Safety and Activity in a Phase 1 Study of CAL-101, an Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood 2010, 116, abstract 1777.
25. Friedman, D.R.; Lanasa, M.C.; Davis, P.H.; Allgood, S.D.; Matta, K.M.; Brander, D.M.; Chen, Y.; Davis, E.D.; Volkheimer, A.D.; Moore, J.O.; et al. Perifosine treatment in chronic lymphocytic leukemia: Results of a phase II clinical trial and in vitro studies. Leuk. Lymphoma 2014, 55, 1067-1075.
26. Hirai, H.; Sootome, H.; Nakatsuru, Y.; Miyama, K.; Taguchi, S.; Tsujioka, K.; Ueno, Y.; Hatch, H.; Majumder, P.K.; Pan, B.-S.; et al. MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumour Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs in vitro and in vivo. Mol. Cancer Ther. 2010, 9, 1956-1967.
27. Witzig, T.E.; Reeder, C.B.; LaPlant, B.R.; Gupta, M.; Johnston, P.B.; Micallef, I.N.; Porrata, L.F.; Ansell, S.M.; Colgan, J.P.; Jacobsen, E.D.; et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25, 341-347.
28. Smith, S.M.; van Besien, K.; Karrison, T.; Dancey, J.; McLaughlin, P.; Younes, A.; Smith, S.; Stiff, P.; Lester, E.; Modi, S.; et al. Temsirolimus Has Activity in Non-Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. J. Clin. Oncol. 2010, 28, 4740-4746.
29. SAR245408-Lymphoma Hub. Available online: http://www.lymphomahub.com/features/sub-featurearticles/sar245408-xl147 (accessed on 6 July 2014).
30. Maira, S.-M.; Pecchi, S.; Huang, A.; Burger, M.; Knapp, M.; Sterker, D.; Schnell, C.; Guthy, D.; Nagel, T.; Wiesmann, M.; et al. Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor. Mol. Cancer Ther. 2012, 11, 317-328.
31. Zang, C.; Eucker, J.; Liu, H.; Coordes, A.; Lenarz, M.; Possinger, K.; Scholz, C.W. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. Leuk. Lymphoma 2014, 55, 425-434.
32. Liu, N.; Rowley, B.R.; Bull, C.O.; Schneider, C.; Haegebarth, A.; Schatz, C.A.; Fracasso, P.R.; Wilkie, D.P.; Hentemann, M.; Wilhelm, S.M.; et al. BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumour Cell Lines and Xenograft Models. Mol. Cancer Ther. 2013, 12, 2319-2330.
33. Castillo, J.J.; Furman, M.; Winer, E.S. CAL-101: A phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin. Investig. Drugs 2011, 21, 15-22.
34. Idelalisib-Containing Combinations Warrant Further Study in Relapsed/Refractory NHL. Available online: http://am.asco.org/idelalisib-containing-combinations-warrant-further-studyrelapsedrefractory-nhl (accessed on 2 September 2014).
35. Okkenhaug, K. Two birds with one stone: dual p110δ and p110γ inhibition. Chem. Biol. 2013, 20, 1309-1310.
36. Horwitz, S.M.; Flinn, I.; Patel, M.R.; Younes, A.; Foss, F.M.; Oki, Y.; Sweeney, J.; Allen, K.; Dunbar, J.; Kelly, P.; et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma. J. Clin. Oncol. 2013, 31, abstract 8518.
37. Cho, D.C.; Hutson, T.E.; Samlowski, W.; Sportelli, P.; Somer, B.; Richards, P.; Sosman, J.A.; Puzanov, I.; Michaelson, M.D.; Flaherty, K.T.; et al. Two Phase II Trials of the Novel Akt Inhibitor Perifosine in Patients with Advanced Renal Cell Carcinoma Following Progression on VEGF-Targeted Therapy. Cancer 2012, 118, 6055-6062.
38. Agarwal, E.; Chaudhuri, A.; Leiphrakpam, P.D.; Haferbier, K.L.; Brattain, M.G.; Chowdhury, S. Akt inhibitor MK-2206 promotes anti-tumour activity and cell death by modulation of AIF and Ezrin in colorectal cancer. BMC Cancer 2014, 14, 145.
39. Xu, Z.-Z.; Xia, Z.-G.; Wang, A.-H.; Wang, W.-F.; Liu, Z.-Y.; Chen, L.-Y.; Li, J.-M. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann. Hematol. 2013, 92, 1351-1358.
40. Coiffier, B.; Ribrag, V. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies. Leuk. Lymphoma 2009, 50, 1916-1930. is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001, 194, 1861-1874.